EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Additive Value of [ 68 Ga]Ga-RM26 PET/CT to [ 68 Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study

Wei Tang, Lin Qi, Minfeng Chen, Ye Zhang, Yongxiang Tang, Shuo Hu, Xiaomei Gao, Yi Cai

Journal of Nuclear Medicine · 2025-05 · 66 (5) · 719-725

DOI: 10.2967/jnumed.124.269189 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 20.03.2025. Verfasst von Wei Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospit…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Heterocyclic Compounds, 1-Ring, Dipeptides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [68Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [68Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [68Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [68Ga]Ga-PSMA-617 PET/CT remains underexplored.

Methods

This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM.

Results

In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [68Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [68Ga]Ga-PSMA-617 PET/CT. [68Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [68Ga]Ga-PSMA-617 PET/CT. The combined use of [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [68Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [68Ga]Ga-PSMA-617 PET/CT. [68Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [68Ga]Ga-PSMA-617 PET/CT. The combined [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99.

Conclusion

In dual-target imaging, [68Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyHeterocyclic Compounds, 1-RingDipeptidesHumansMaleAgedLymphatic MetastasisMiddle AgedProspective StudiesGallium RadioisotopesPelvisGallium IsotopesEdetic AcidProstate-Specific Antigen

Stichwörter der Autor:innen

FOLH1 proteinPET/CTbombesin receptorslymphatic metastasisprostatic neoplasms

Substanzen

Heterocyclic Compounds, 1-RingGallium RadioisotopesDipeptidesPSMA-617Gallium IsotopesEdetic AcidProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Oncology, NHC Key Laboratory of Cancer Proteomics, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University…
  • Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; xyyf0401@qq.co…
  • Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, China; and.
  • Department of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China xyyf0401@qq.com hushuo…
  • Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; xyyf0401@qq.com hushuo2…

Zitieren

APA

Tang, W., Qi, L., Chen, M., Zhang, Y., Tang, Y., Hu, S., Gao, X., & Cai, Y. (2025). Additive Value of [ 68 Ga]Ga-RM26 PET/CT to [ 68 Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study. Journal of Nuclear Medicine, 66(5), 719-725. https://doi.org/10.2967/jnumed.124.269189

Vancouver

Tang W, Qi L, Chen M, Zhang Y, Tang Y, Hu S, et al. Additive Value of [ 68 Ga]Ga-RM26 PET/CT to [ 68 Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study. Journal of Nuclear Medicine. 2025;66(5):719-725. doi:10.2967/jnumed.124.269189

BibTeX
@article{Tang2025,
  author = {Tang, Wei and Qi, Lin and Chen, Minfeng and Zhang, Ye and Tang, Yongxiang and Hu, Shuo and Gao, Xiaomei and Cai, Yi},
  title = {Additive Value of [ 68 Ga]Ga-RM26 PET/CT to [ 68 Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {5},
  pages = {719--725},
  doi = {10.2967/jnumed.124.269189}
}
Kostenlos starten →